← Back to Search

Vascular lesions for Nervous System Disorders

Phase 2
Waitlist Available
Led By Edward A Neuwelt, MD
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial is testing whether a new iron particle contrast agent, ferumoxytol, is safe and more efficient than the standard substance, gadolinium, in viewing the vessels of the brain and areas in the brain on magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA).

Eligible Conditions
  • Nervous System Disorders
  • Diagnostic Imaging

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of Border Delineation
Degree of Contrast Enhancement
Internal Morphology of Lesions
+1 more
Secondary outcome measures
Ferumoxytol Particles With Histology and Electron Microscopy in Biopsy Samples
Iron Uptake and Clearance in Abdominal Organs, Such as the Liver, Spleen, Pancreas and Bone Marrow by Applying Usual Abdominal MR Sequences at Multiple Time Points
Side Effects/Safety of Ferumoxytol When Given During MRI.

Trial Design

3Treatment groups
Active Control
Group I: Vascular lesionsActive Control1 Intervention
subjects will include those with vascular CNS lesions such as ischemic stroke, transient ischemic attack (TIA) with suspected carotid embolic origin, or vasculopathy involving the carotids, (including diagnosed carotid stenosis >50%) the aorta, or the arteries of the extremities, or diagnosed thrombosis of the intraabdominal, pelvic or extremity veins.
Group II: Inflammatory lesionsActive Control1 Intervention
Subjects with dural, central nervous system (CNS) parenchymal based inflammatory, vascular or demyelinating lesions.
Group III: Lymph nodesActive Control1 Intervention
Subjects with enlarged cervical lymph nodes in which inflammatory processes (reactive lymph nodes) is part of the differentials.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
973 Previous Clinical Trials
7,385,557 Total Patients Enrolled
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,340 Previous Clinical Trials
649,106 Total Patients Enrolled
Edward A Neuwelt, MDPrincipal InvestigatorOregon Health and Science University
5 Previous Clinical Trials
208 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
Edward Neuwelt 2004. "MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00659776.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top